US Stock Futures Signal Higher Start On Wall Street
US stock futures traded higher in early pre-market trade. Futures for the Dow Jones Industrial Average jumped 89.50 points to 17,974.50, while the Standard & Poor's 500 index futures rose 7.45 points to 2,088.95. Futures for the Nasdaq 100 index rose 15.60 points to 4,437.60.
A Peek Into Global Markets
European markets were mostly higher today, with the Spanish Ibex Index rising 0.43%, STOXX Europe 600 Index falling 0.02% and German DAX 30 index rising 0.73%. French CAC 40 Index gained 0.22% and London's FTSE 100 Index rose 0.09%.
In Asian markets, Japan's Nikkei Stock Average climbed 0.43%, Hong Kong's Hang Seng Index fell 0.38%, China's Shanghai Composite Index gained 0.98% and India's BSE Sensex slipped 0.73%.
Analysts at Oppenheimer upgraded Pier 1 Imports, Inc. (NYSE: PIR) from Market Perform to Outperform. The price target for Pier 1 Imports is set to $20.00.
Pier 1 Imports shares rose 2.16% to $13.70 in pre-market trading.
- Intercept Pharmaceuticals (NASDAQ: ICPT) announced today new subgroup analyses from the Phase 2b FLINT trial of obeticholic acid (OCA) in patients with nonalcoholic steatohepatitis (NASH). To read the full news, click here.
- Today Biogen Idec (NASDAQ: BIIB) announced data from a pre-specified interim analysis of PRIME, the Phase 1b study of aducanumab (BIIB037), in which aducanumab demonstrated an acceptable safety profile and positive results on radiologic and clinical measurements in patients with prodromal or mild Alzheimer's disease (AD). To read the full news, click here.
- Myriad Genetics (NASDAQ: MYGN) today announced that results from the EMPATHY-P clinical study of Prolaris in patients newly diagnosed with prostate cancer will be highlighted at the 30th Annual Congress of the European Association of Urology. To read the full news, click here.
- Shares of Darden Restaurants Inc. (NYSE: DRI) surged more than 4% in pre-market trading after the company reported stronger-than-expected earnings for the third quarter. To read the full news, click here.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.